Trade Names and Dosing for Romiplostim and Avatrombopag
Romiplostim is marketed as Nplate and avatrombopag as DOPTELET, with distinct dosing regimens that differ fundamentally between these two thrombopoietin receptor agonists. 1, 2
Romiplostim (Nplate)
Trade Name: Nplate 1
Formulation: Subcutaneous injection supplied as lyophilized powder in 125 mcg, 250 mcg, or 500 mcg vials that reconstitute to 500 mcg/mL 1
Dosing for Immune Thrombocytopenia (ITP):
- Initial dose: 1 mcg/kg subcutaneously once weekly 1
- Dose adjustments: Increase by 1 mcg/kg/week increments based on platelet response
- Goal: Maintain platelet count ≥50 × 10⁹/L to reduce bleeding risk
- Maximum dose: 10 mcg/kg weekly 1
Important Dosing Context: While FDA labeling recommends starting at 1 mcg/kg, real-world practice often initiates at 2-4 mcg/kg depending on thrombocytopenia severity 3. The 2020 expert panel guidance suggests tapering by reducing 1 mcg/kg/week every 2 weeks once stable response is achieved 4.
Avatrombopag (DOPTELET)
Trade Name: DOPTELET 2
Formulation: Oral tablets 2
Dosing for Chronic Immune Thrombocytopenia (ITP):
- Initial dose: 20 mg (1 tablet) once daily with food 2
- Monitoring: Assess platelet counts weekly until stable ≥50 × 10⁹/L, then monthly
- Dose adjustments:
- If platelets <50 × 10⁹/L after ≥2 weeks: Increase one dose level (20 mg → 40 mg)
- If platelets 200-400 × 10⁹/L: Decrease one dose level
- If platelets >400 × 10⁹/L: Hold drug, restart at lower dose when <150 × 10⁹/L
- Maximum dose: 40 mg daily 2
Dosing for Chronic Liver Disease (Pre-Procedure):
- Timing: Begin 10-13 days before scheduled procedure 2
- Duration: 5 consecutive days with food
- Dose based on baseline platelet count:
- Platelets <40 × 10⁹/L: 60 mg (3 tablets) daily × 5 days
- Platelets 40 to <50 × 10⁹/L: 40 mg (2 tablets) daily × 5 days
- Procedure timing: Perform 5-8 days after last dose 2
Key Clinical Distinctions
Route of administration is the most obvious difference: romiplostim requires weekly subcutaneous injections while avatrombopag offers oral convenience 2, 1. This makes avatrombopag particularly attractive for patients who prefer to avoid injections or have difficulty with clinic visits.
For chemotherapy-induced thrombocytopenia (your FOLFOX context), neither drug has FDA approval for this indication. However, romiplostim has been used off-label with some success 5. In a retrospective series of 20 patients with chemotherapy-induced thrombocytopenia, romiplostim at mean dose 2.9 mcg/kg achieved platelet recovery ≥100 × 10⁹/L in 19/20 patients, allowing resumption of chemotherapy 5. The study used weekly romiplostim continued during chemotherapy cycles, which differs from standard ITP management.
Critical safety consideration: The 2021 AASLD guidance notes that early eltrombopag trials in liver disease were discontinued due to excess thrombotic events when targeting normal platelet ranges 6. While avatrombopag and lusutrombopag showed no statistical difference in thrombotic complications versus placebo in their approval trials, they also showed no statistical difference in bleeding prevention 6. This underscores that routine prophylactic use to prevent procedure-related bleeding cannot be recommended based on current evidence 6.
Monitoring requirements differ: romiplostim necessitates weekly platelet monitoring initially, while avatrombopag requires weekly monitoring until stable, then monthly 2, 1. Both require monitoring for at least 4 weeks after discontinuation 2.
For your specific FOLFOX scenario: There is no FDA-approved indication for either agent in chemotherapy-induced thrombocytopenia. The limited data with romiplostim suggests potential benefit, but this remains off-label use requiring careful risk-benefit assessment and close monitoring for thrombotic complications 5, 3.